Vendor comparison · 2026
GHRP-2 vendors: 5 compared on COAs and price
Tissue & recoveryAlso known as Pralmorelin, KP-102
Evidence tier
Substantial published literature
256 publications over 33 years · trials not yet curated
- Vendors carrying it
- 5
- 5 with a listed price
- Vendors with checkable COAs
- 1
- 1 publish any certificate
- Lots tested
- 1
- 1 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 3 Sept 2026
- oldest 3 Sept 2026
- Laboratories named
- 1
- most often AV Analytics
- Median label gap
- 2.0%
- 100% of lots within 5% of label
- Median purity
- 99.81%
- 1 of 1 lots at 99% or above
- Lowest price per mg
- $3.90
- peer median $4.00
- Publications located
- 256
- researched since 1993
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Bench Grade Peptides has the most checkable GHRP-2 testing in this index: 1 lot assayed by AV Analytics, the newest on 3 Sept 2026. The lowest listed price is $3.90 per mg at Simple Peptide, against a peer median of $4.00. 5 vendors carrying GHRP-2 are compared below. 1 publish at least one certificate naming a checkable laboratory, 1 lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying GHRP-2
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Simple Peptide | 79.692% | $3.90 (98%) | 0 | — | — | — | — | no reportVisit site |
| 2 | Bench Grade Peptides | 67.789% | $12.20 (250%) | 1 / 1 | AV Analytics | 99.8% | 2.0% | ||
| 3 | GenX Peptides | 65.869% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 4 | Biotech Peptides | 62.160% | $4.00 (100%) | 0 | — | — | — | — | no reportVisit site |
| 5 | Evo Labs Research | 59.387% | $8.00 (200%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of GHRP-2 is on file. All 1 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
1 of 1 lots at 99% or above; median 99.81%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 0 |
| ≥99.5% | 1 |
100% of lots within 5% of the labelled mass; median gap 2.0%.
| Range | lots |
|---|---|
| ≤2% | 1 |
| 2–5% | 0 |
| 5–10% | 0 |
| 10–20% | 0 |
| >20% | 0 |
5 vendors, $3.90 to $12.20; median $4.00.
| Range | vendors |
|---|---|
| $2.00–$4.00 | 1 |
| $4.00–$6.00 | 2 |
| $6.00–$8.00 | 0 |
| $8.00–$10.00 | 1 |
| $10.00–$12.00 | 0 |
| $12.00–$14.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| AV Analytics | 1 | 1 | 100% | No public lookup found |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 Bench Grade Peptides | 00011/0011 | AV Analytics | 5 mg | 5.1 mg | 2.0% | 99.8% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1993 — 33 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
256 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.8% across 1 certificate
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
single lot on record, mean label deviation 2.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
5 of 5 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
1 of 1 certificate from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is GHRP-2?
A growth-hormone-releasing peptide (also known as pralmorelin) studied for stimulating growth hormone secretion.
Studied in published research for growth-hormone release and recovery.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in human growth-hormone-secretion research; approved as a diagnostic in some countries. PepIndex does not evaluate clinical significance and does not describe administration.
- Ipamorelin, the first selective growth hormone secretagogue — European journal of endocrinology (1998)
Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1998).
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN — Drugs in R&D (2004)
Peer-reviewed article indexed in PubMed, published in Drugs in R&D (2004).
- Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry — Rapid communications in mass spectrometry : RCM (2010)
Peer-reviewed article indexed in PubMed, published in Rapid communications in mass spectrometry : RCM (2010).
- The Safety and Efficacy of Growth Hormone Secretagogues — Sexual medicine reviews (2018)
Peer-reviewed article indexed in PubMed, published in Sexual medicine reviews (2018).
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational andrology and urology (2020)
Peer-reviewed article indexed in PubMed, published in Translational andrology and urology (2020).
- Growth hormone-releasing peptides — European journal of endocrinology (1997)
Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1997).
- Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells — Endocrine (1998)
Peer-reviewed article indexed in PubMed, published in Endocrine (1998).
- GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans — Journal of pediatric endocrinology & metabolism : JPEM (1996)
Peer-reviewed article indexed in PubMed, published in Journal of pediatric endocrinology & metabolism : JPEM (1996).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.